Cysteamine bitartrate: Phase IIb started

Raptor began the double-blind, placebo-controlled, U.S. Phase IIb CyNCh trial to evaluate 600, 750 and 900 mg/day RP103 for 52 weeks in 160 patients ages 8-17 years. NIH's National Institute of Diabet...